Skip to main content
    E

    enGene Therapeutics Inc. (ENGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.89
    -0.52 (-21.58%)

    Market Cap: $161.51M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    enGene Therapeutics Inc. (ENGN) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to enGene Therapeutics are MacroGenics (MGNX), Cellectis SA (CLLS) and NeOnc Technologies Holdings, Inc. Common Stock (NTHI). By market cap, enGene Therapeutics ranks 8th of the 13 companies on this page; Neurogene (NGNE) is the largest at $495.37M.

    Peer Comparison

    ENGN's ROIC of -42.2% is above the peer median of -51.3%, and its revenue growth of 0.0% is above the median of -62.9%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    enGene Therapeutics (ENGN)$161.51MN/AN/A0.0%-42.2%0.0%0.00%
    MacroGenics Inc (MGNX)$140.60MN/A1.2x-36.6%-108.7%-64.8%0.00%
    Cellectis SA (CLLS)$118.86MN/A1.8x0.0%-74.1%-85.4%0.00%
    NeOnc Technologies Holdings, Inc. Common Stock (NTHI)$141.66MN/AN/A0.0%N/A-100.0%0.00%
    Genelux Corporation Common Stock (GNLX)$84.38MN/AN/A0.0%N/A-95.3%0.00%
    Eledon Pharmaceuticals Inc (ELDN)$178.63MN/AN/A0.0%N/A0.0%0.00%
    Neurogene Inc (NGNE)$495.37MN/AN/A0.0%-28.5%0.0%0.00%
    Enanta Pharmaceuticals Inc (ENTA)$320.09MN/A4.8x-96.9%N/A-21.6%0.00%
    ProQR Therapeutics BV (PRQR)$199.28MN/A6.1x-228.2%N/A120.4%0.00%
    LENZ Therapeutics Inc (LENZ)$129.77MN/A9.7x0.0%N/A-72.9%0.00%
    Greenwich Lifesciences Inc (GLSI)$219.29MN/AN/A0.0%N/A0.0%0.00%
    Lineage Cell Therapeutics Inc (LCTX)$231.35MN/A18.7x16.2%-6.7%-61.0%0.00%
    Sol Gel Technologies Ltd (SLGL)$180.46MN/A125.4x0.0%N/A-96.6%0.00%
    Peer median$179.55MN/A6.1x0.0%-51.3%-62.9%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to enGene Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    MacroGenics Inc (MGNX)
    MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States.
    MGNX competitors
    Cellectis SA (CLLS)
    Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors...
    CLLS competitors
    NeOnc Technologies Holdings, Inc. Common Stock (NTHI)
    NeOnc Technologies Holdings, Inc. is a pioneering biotechnology firm dedicated to revolutionizing cancer treatment through its advanced immunotherapy...
    NTHI competitors
    Genelux Corporation Common Stock (GNLX)
    Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering...
    GNLX competitors
    Eledon Pharmaceuticals Inc (ELDN)
    Eledon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing drugs for patients living with autoimmune diseases...
    ELDN competitors
    Neurogene Inc (NGNE)
    Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders...
    NGNE competitors
    Enanta Pharmaceuticals Inc (ENTA)
    Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases.
    ENTA competitors
    ProQR Therapeutics BV (PRQR)
    ProQR Therapeutics NV, a biopharmaceutical company, is dedicated to the discovery and development of RNA-based therapies for the treatment of genetic disorders.
    PRQR competitors
    LENZ Therapeutics Inc (LENZ)
    LENZ Therapeutics Inc is a cutting-edge biopharmaceutical company dedicated to developing transformative therapies for neurological disorders...
    LENZ competitors
    Greenwich Lifesciences Inc (GLSI)
    Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for breast and other HER2 /...
    GLSI competitors
    Lineage Cell Therapeutics Inc (LCTX)
    Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment...
    LCTX competitors
    Sol Gel Technologies Ltd (SLGL)
    Sol-Gel Technologies Ltd., a specialty clinical-stage pharmaceutical company, is focused on developing and commercializing topical dermatological...
    SLGL competitors

    Frequently Asked Questions About ENGN

    Who are enGene Therapeutics' main competitors?

    The companies most similar to enGene Therapeutics include MacroGenics (MGNX), Cellectis SA (CLLS), NeOnc Technologies Holdings, Inc. Common Stock (NTHI), Genelux Corporation Common Stock (GNLX) and Eledon Pharmaceuticals (ELDN), listed from the closest match.

    Who is enGene Therapeutics' biggest competitor?

    Neurogene (NGNE) is the largest of the similar companies at $495.37M; MacroGenics (MGNX) is the closest match by business profile, size, sector and industry.

    How does ENGN stock compare with its competitors?

    ENGN's net margin is 0.0% against a peer median of 0.0%.

    Which of enGene Therapeutics' competitors pays a higher dividend?

    enGene Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is enGene Therapeutics bigger than its competitors?

    No. enGene Therapeutics is 8th by market cap among the 13 companies on this page; the largest is Neurogene (NGNE) at $495.37M.